Related Experiment Video
Updated: Jul 26, 2026
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
Treating Traumatic Brain Injury with Minocycline
Peter J Bergold1,2, Rachel Furhang3, Siobhán Lawless3
1Graduate Programs in Neural and Behavioral Sciences, State University of New York Downstate Health Sciences University, 450 Clarkson Avenue, Brooklyn, New York, NY, 11203, USA. Peter.bergold@downstate.edu.
Abstract:
Traumatic brain injury (TBI) results in both rapid and delayed brain damage. The speed, complexity, and persistence of TBI present large obstacles to drug development. Preclinical studies from multiple laboratories have tested the FDA-approved anti-microbial drug minocycline (MINO) to treat traumatic brain injury. At concentrations greater than needed for anti-microbial action, MINO readily inhibits microglial activation. MINO has additional pleotropic effects including anti-inflammatory, anti-oxidant, and anti-apoptotic activities. MINO inhibits multiple proteins that promote brain injury including metalloproteases, caspases, calpain, and polyADP-ribose-polymerase-1. At these elevated doses, MINO is well tolerated and enters the brain even when the blood-brain barrier is intact. Most preclinical studies with a first dose of MINO at less than 1 h after injury have shown improved multiple outcomes after TBI. Fewer studies with more delayed dosing have yielded similar results. A small number of clinical trials for TBI have established the safety of MINO and suggested some drug efficacy. Studies are also ongoing that either improve MINO pharmacology or combine MINO with other drugs to increase its therapeutic efficacy against TBI. This review builds upon a previous, recent review by some of the authors (Lawless and Bergold, Neural Regen Res 17:2589-92, 2022). The present review includes the additional preclinical studies examining the efficacy of minocycline in preclinical TBI models. This review also includes recommendations for a clinical trial to test MINO to treat TBI.
Insights
Minocycline (MINO) shows promise for treating traumatic brain injury (TBI) by reducing inflammation and cell death. Further clinical trials are recommended to confirm its efficacy and safety in TBI patients.
Area of Science:
- Neuroscience
- Pharmacology
- Trauma Research
Background:
- Traumatic brain injury (TBI) causes complex, persistent damage, hindering drug development.
- Minocycline (MINO), an FDA-approved antimicrobial, is investigated for TBI due to its neuroprotective properties.
- MINO's efficacy at higher, non-antimicrobial doses is linked to inhibiting microglial activation and other injury-promoting proteins.
Purpose of the Study:
- To review preclinical and clinical evidence for minocycline (MINO) in treating traumatic brain injury (TBI).
- To highlight MINO's pleiotropic effects, including anti-inflammatory, anti-oxidant, and anti-apoptotic activities.
- To provide recommendations for future clinical trials investigating MINO for TBI.
Main Methods:
- Review of preclinical studies using MINO in TBI models.
- Analysis of existing clinical trial data on MINO safety and efficacy in TBI.
- Examination of MINO's pharmacological actions, including blood-brain barrier penetration and protein inhibition.
Main Results:
- Most preclinical studies show improved outcomes with early MINO administration post-TBI.
- Delayed MINO dosing also demonstrates positive results in fewer studies.
- Clinical trials confirm MINO's safety and suggest potential therapeutic benefits for TBI.
Conclusions:
- Minocycline (MINO) exhibits significant neuroprotective potential in preclinical TBI models.
- Ongoing research focuses on optimizing MINO's efficacy through improved pharmacology and combination therapies.
- Evidence supports the progression to larger clinical trials to establish MINO as a TBI treatment.
